Award
National Cancer Institute 5R01CA262788-05
Targeting of Doppel-axis to Control Lung Tumor Angiogenesis and Immunity
Recipient
University of Utah
Award Amount
$352,275.00
Ceiling
$352,275.00
Awarded
June 05, 2026
Identifier
5R01CA262788-05
A research project funded by the National Cancer Institute to develop targeted therapies against lung tumor angiogenesis by focusing on the doppel protein, aiming to reduce side effects and improve treatment efficacy.
Description
This project aims to target a protein called doppel, expressed only in tumor-associated endothelial cells, to inhibit tumor angiogenesis specifically, reducing side effects and enhancing therapy efficacy. It involves elucidating doppel's role in tumor progression, evaluating anti-doppel monoclonal antibodies in mouse models, and exploring how Dplhi-TECs influence the lung tumor immune microenvironment.